See related research by the Irish Critical Care Trials Group, <http://ccforum.com/content/12/5/R121>

*Who wins in battle makes many calculations before the battle is fought*.

(Sun Tzu, *The Art of War*, c.500 BC)

The challenge of conducting high-quality clinical studies in the critically ill population is widely recognised. Heterogeneity in patient populations and clinical practice, diagnostic uncertainty, concerns with consent, and the overlapping nature of the presenting illnesses are amongst the inherent difficulties. Influential studies in this population therefore increasingly involve multicentre, collaborative efforts using rigorously defined inclusion criteria and outcome measures -- such projects aim to obviate the aforementioned difficulties and to reduce the influence of individual intensive care units (ICUs) and case-mix variations on the findings. Ultimately, the quality of the data justifies the logistical challenge involved. For this reason, the recent article from the newly-formed Irish Critical Care Trials Group is a welcome announcement of a further such alliance \[[@B1]\].

The data presented describe 1,029 patients admitted to ICU services in a 10-week period in 2006, covering a slight majority of all ICU beds in Ireland. The data include national specialist centres and university teaching hospitals, as well as regional units. The overall pattern depicts a busy service, with 78% of admissions being emergent in nature, a mean Sequential Organ Failure Assessment score of 5.4, and 70% of patients needing mechanical ventilation. Previous research in Ireland -- showing an ICU bed occupancy rate of 97%, an unscheduled discharge rate of 23%, and frequent cancellation of elective surgery -- is consistent with this pattern \[[@B2]\]. The ICU readmission rate of 7.5% is perhaps attributable to these service realities -- as indeed may be the failure to collect data in four of the 14 units that entered the study, including 23% of relevant patients.

While accepting that the missing patient data compromise the validity of the findings, the outcomes nonetheless appear compatible with international standards and indeed are broadly indicative of the success of modern intensive care medicine. More than 80% of patients survived their ICU stay. The outcomes in the subgroups are more striking: over 75% of readmitted patients survived and, of the 93 patients with five or six systems failing on admission, just over one-half survived.

Compatibility with international outcomes is perhaps most evident from those diagnostic categories where standard, consensus definitions are established. For severe sepsis, the ICU mortality of 24% compares with a reported 35% in England, Wales and Northern Ireland for severe sepsis in the first 24 hours \[[@B3]\]. For acute lung injury/acute respiratory distress syndrome, the Irish mortality was 32% -- and the Irish Critical Care Trials Group has previously shown that this is consistent with modern international studies in the protective ventilation era \[[@B4]\]. Although the numbers are relatively small (n = 289), an ICU mortality of 38% for renal failure compares unfavourably with the hospital mortality of 26.3% reported by Hoste and colleagues using the same criteria \[[@B5]\]. Nonetheless, the study arguably further validates these RIFLE (Risk-Injury-Failure-Loss-End stage) descriptors as outcome predictors in acute renal dysfunction \[[@B5]\].

Certain shortcomings are inevitable in this research format. Seasonal and regional variations cannot be detected as data from a short collection period are pooled together. Nothing can be inferred about decision-making processes. The use of ICU mortality alone as a measure of outcome is not ideal, and more meaningful outcome assessment tools including hospital mortality should be utilised in future projects \[[@B6]\]; for example, patients who were refused readmission and who might have gone on to die in hospital wards will appear as survivors in such a crude analysis. Future scientific publications should also avoid the irritation of new data introduction in the discussion of the findings.

The value of the present data will be more fully realised when the Irish Critical Care Trials Group produces further, hypothesis-testing studies. Having taken advice from the ANZICS Critical Care Trials Group, the Irish Critical Care Trials Group set out to achieve this epidemiological study to provide baseline information for research planning. The data provide insight into disease prevalence (for example, of acute respiratory distress syndrome), and enable planning for the study duration and resource allocation once power analysis has indicated the size of the study population required. The demonstration of the willingness of team members to cooperate and of the capacity of information systems to gather and collate such information is a further key to such studies and collaborations.

The authors identify an urgent requirement for audit resources to maintain the ambition shown by this study. Participation in the UK\'s Intensive Care National Audit and Research Centre would be one option, opening up the possibility of a UK/Irish database. Alternatively, broader international collaborations might work. The ability demonstrated by the Irish Critical Care Trials Group study to establish a research ethos that straddles the relatively contentious border linking the Irish Republic with the United Kingdom is scientifically encouraging.
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